ELMSFORD, NY (November 8, 2005) - U.S. Patent No. 6,962,816 , entitled "Highly Controllable Electroporation and Application Thereof" issued on November 8, 2005. Congratulations to Dr. Sadeg M. Faris. This patent adds to Reveo's portfolio in the field of biotechnology. Conventionally, electroporation is used in laboratory settings to inject chemical and biological compounds into a cell, avoiding the reliance on the cell's own protein receptors and trans-membrane channels for transport across the cell membrane. This allows researchers to easily study the biological affect of compounds, be it a potentially life-saving cancer drug or a deadly biological toxin. However, current electroporation techniques are limited. The present invention solves this problem with a broad effect sub-system and a narrow effect sub-system to control the size, number, and/or location of pores. Filters and other devices also are claimed using the narrow and broad effect sub-systems.
Anyone interested in licensing this portfolio should contact Ralph.Crispino@Reveo.com.